The FUCA2 antibody targets the alpha-L-fucosidase 2 (FUCA2) enzyme, a glycosidase involved in hydrolyzing α-1.6-linked fucose residues from glycoproteins and glycolipids. Unlike its isoform FUCA1. which is lysosomal, FUCA2 is secreted and functions extracellularly, potentially modulating cell-matrix interactions and signaling pathways. FUCA2 is expressed in various tissues, including the liver, kidneys, and reproductive organs, and has been implicated in physiological processes such as fertilization, inflammation, and cancer progression.
Research on FUCA2 antibodies has grown due to their utility in studying FUCA2's role in disease. For instance, reduced FUCA2 expression has been associated with tumor metastasis in certain cancers, suggesting its potential as a biomarker or therapeutic target. Antibodies against FUCA2 enable detection of its expression levels and localization in tissues or biological fluids, aiding in mechanistic studies. Additionally, FUCA2 dysregulation has been linked to neurological disorders and fucosidosis-like symptoms, though its exact pathological contributions remain under investigation. The development of specific, high-affinity FUCA2 antibodies continues to support functional analyses, including ELISA, immunohistochemistry, and Western blotting, advancing understanding of its biological and clinical significance.